Search

Your search keyword '"Neelapu, Sattva"' showing total 2,135 results
Start Over Author "Neelapu, Sattva"
2,135 results on '"Neelapu, Sattva"'

151. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Author

Li, Xubin, primary, Deng, Qing, additional, Henderson, Jared, additional, Watson, Grace, additional, Deaton, Laurel, additional, Cain, Taylor, additional, Fayad, Luis, additional, Iyer, Swaminathan Padmanabhan, additional, Hagemeister, Fredrick B., additional, Nastoupil, Loretta J., additional, Fowler, Nathan H., additional, Westin, Jason, additional, Steiner, Raphael, additional, Nair, Ranjit, additional, Ahmed, Sairah, additional, Alatrash, Gheath, additional, Neelapu, Sattva S., additional, Strati, Paolo, additional, and Green, Michael R, additional

Published
2022
Full Text
View/download PDF

152. Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma

Author

Pinnix, Chelsea C., primary, Dabaja, Bouthaina S., additional, Gunther, Jillian R., additional, Fang, Penny, additional, Wu, Susan, additional, Ahmed, Sairah, additional, Steiner, Raphael E, additional, Nair, Ranjit, additional, Strati, Paolo, additional, Westin, Jason, additional, Fayad, Luis, additional, Iyer, Swami P., additional, Rodriguez, Maria Alma, additional, Lee, Hun Ju, additional, Samaniego, Felipe, additional, Chihara, Dai, additional, Jain, Preetesh, additional, Feng, Lei, additional, Flowers, Christopher R., additional, Neelapu, Sattva S., additional, and Nastoupil, Loretta J., additional

Published
2022
Full Text
View/download PDF

153. Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy

Author

Jallouk, Andrew, primary, Feng, Lei, additional, Noorani, Mansoor, additional, Das, Kaberi, additional, Steiner, Raphael E, additional, Nastoupil, Loretta J., additional, Hawkins, Misha, additional, Nair, Ranjit, additional, Westin, Jason, additional, Fayad, Luis, additional, Chihara, Dai, additional, Malpica Castillo, Luis Enrique, additional, Iyer, Swaminathan P., additional, Ahmed, Sairah, additional, Shpall, Elizabeth J, additional, Kebriaei, Partow, additional, Neelapu, Sattva S., additional, and Strati, Paolo, additional

Published
2022
Full Text
View/download PDF

154. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis

Author

Agbedia, Owhofasa O., primary, Prakash, Rishab, additional, Xu, Jie, additional, Becnel, Melody R., additional, Nair, Ranjit, additional, Steiner, Raphael E, additional, Feng, Lei, additional, Lee, Hun Ju, additional, Strati, Paolo, additional, Ahmed, Sairah, additional, Parmar, Simrit, additional, Nieto, Yago, additional, Hosing, Chitra, additional, Westin, Jason, additional, Nastoupil, Loretta J., additional, Vo, Ann, additional, Samaniego, Felipe, additional, Fowler, Nathan H., additional, Saini, Neeraj, additional, Khouri, Issa F., additional, Im, Jin S., additional, Fayad, Luis, additional, Jain, Preetesh, additional, Wang, Michael L., additional, Miranda, Roberto N., additional, Vega, Francisco, additional, Medeiros, Jeffrey, additional, Oki, Yasuhiro, additional, Flowers, Christopher R., additional, Neelapu, Sattva S., additional, and Iyer, Swaminathan P., additional

Published
2022
Full Text
View/download PDF

155. Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy

Author

Tang, Kevin, primary, Khwaja, Raamis, additional, Feng, Lei, additional, Strati, Paolo, additional, Steiner, Raphael E., additional, Nair, Ranjit, additional, Flowers, Christopher R., additional, Saini, Neeraj, additional, Ramdial, Jeremy L., additional, Srour, Samer A., additional, Champlin, Richard E., additional, Rondon, Gabriela, additional, Torres, Janet, additional, Kebriaei, Partow, additional, Nastoupil, Loretta J., additional, Mistry, Haleigh, additional, Shpall, Elizabeth J., additional, Nieto, Yago, additional, Westin, Jason, additional, Neelapu, Sattva S., additional, and Ahmed, Sairah, additional

Published
2022
Full Text
View/download PDF

156. Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.

Author

Nair, Ranjit, primary, Prakash, Rishab, additional, Dang, Anna, additional, Gunther, Jillian R., additional, Huen, Auris, additional, Xu, Jie, additional, Malpica Castillo, Luis Enrique, additional, Torres Cabala, Carlos, additional, Heberton, Meghan, additional, Fang, Penny, additional, Ahmed, Sairah, additional, Miranda, Roberto N., additional, Fayad, Luis, additional, Steiner, Raphael, additional, Lee, Hun Ju, additional, Chihara, Dai, additional, Jain, Preetesh, additional, Srour, Samer A, additional, Ramdial, Jeremy L, additional, Nieto, Yago, additional, Nastoupil, Loretta J., additional, Pinnix, Chelsea C., additional, Neelapu, Sattva S., additional, Flowers, Christopher R., additional, Medeiros, L. Jeffrey, additional, Hosing, Chitra, additional, Wang, Michael L., additional, Dabaja, Bouthaina S., additional, Vega, Francisco, additional, Feng, Lei, additional, and Iyer, Swaminathan Padmanabhan, additional

Published
2022
Full Text
View/download PDF

157. Network Meta-Analysis (NMA) of Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after 2 Prior Treatments Using Published Comparative Studies

Author

Locke, Frederick L., primary, Neelapu, Sattva S., additional, Ray, Markqayne D., additional, Limbrick-Oldfield, Eve H, additional, Wade, Sally W, additional, Kanters, Steve, additional, Patel, Anik R., additional, and Oluwole, Olalekan O., additional

Published
2022
Full Text
View/download PDF

158. Development of a Novel Platform for in-Vitro Immune-Monitoring of Antigen-Specific T Cells and Discovery of Novel Antigen-Specific TCRs Using Immortalized B Cells Transfected with mRNA of Antigen Fused to Mitd (IBMAM)

Author

Zhang, Tiantian, primary, Wang, Zhe, additional, Cha, Soung-chul, additional, Anderson, Aaron, additional, Liu, Jingwei, additional, Dong, Zhenyuan, additional, Szymura, Szymon, additional, Kuang, Benjamin, additional, Oh, Elizabeth, additional, Neelapu, Sattva S., additional, and Kwak, Larry W., additional

Published
2022
Full Text
View/download PDF

159. 296 Targeting B-cell malignancies with anti-ROR1 CAR T-cell therapy

Author

Weng, Jinsheng, primary, Agbedia, Owhofasa, additional, Cao, Jingjing, additional, Cheng, Xiaoyun, additional, Kuang, Shao Qing, additional, Chu, Fuliang, additional, Patchv, Sridevi, additional, Tang, Yongfu, additional, Bansal, Divyam, additional, Liu, Jingwei, additional, Saini, Neeraj, additional, and Neelapu, Sattva, additional

Published
2022
Full Text
View/download PDF

160. 1454 Multiomics and multimodal analysis approach to construct a diffuse large B cell lymphoma atlas of tumor microenvironment for predictive modeling

Author

Mattie, Mike, primary, Perbost, Regis, additional, Turcan, Sarah, additional, Danan, Corinne, additional, Locke, Frederick, additional, Neelapu, Sattva, additional, Miklos, David, additional, Jacobson, Caron, additional, Lekakis, Lazaros, additional, Lin, Yi, additional, Ghobadi, Armin, additional, Kim, Jenny, additional, Wang, Zixing, additional, Xue, Allen, additional, Filosto, Simone, additional, Scholler, Nathalie, additional, and Galon, Jérôme, additional

Published
2022
Full Text
View/download PDF

161. Additional file 4 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Author

Liu, Shuying, Xie, Shelly M., Liu, Wenbin, Gagea, Mihai, Hanker, Ariella B., Nguyen, Nguyen, Singareeka Raghavendra, Akshara, Yang-Kolodji, Gloria, Chu, Fuliang, Neelapu, Sattva S., Marchese, Adriano, Hanash, Samir, Zimmermann, Johann, Arteaga, Carlos L., and Tripathy, Debasish

Abstract

Additional file 4. Figure S4. Effect of AMD3100 on pathways. BTRT cells grown in 3D Matrigel culture were treated with vehicle, AMD3100, trastuzumab, or their combination. Cell lysates were subject to RPPA. A portion of the RPPA data were further analyzed with one-way ANOVA.

Published
2023
Full Text
View/download PDF

162. Additional file 8 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Author

Liu, Shuying, Xie, Shelly M., Liu, Wenbin, Gagea, Mihai, Hanker, Ariella B., Nguyen, Nguyen, Singareeka Raghavendra, Akshara, Yang-Kolodji, Gloria, Chu, Fuliang, Neelapu, Sattva S., Marchese, Adriano, Hanash, Samir, Zimmermann, Johann, Arteaga, Carlos L., and Tripathy, Debasish

Abstract

Additional file 8. Figure S8: Characteristic of the trastuzumab-resistant mouse model and effect of combined treatments on cell signaling. A five-week-old female athymic nude mice were implanted with 0.36 mg, 90-day release, 17beta-estradiol pellets. Three days later, in total 5x106 BT-T or HR6 cells in 150 μl growth factor reduced Matrigel and PBS were orthotopically injected. Once tumors reached a volume ~100 mm3, the mice were randomly grouped and received treatment with trastuzumab. Tumor sizes were measured with calipers twice weekly. Tumor volume was calculated with the formula V = lw2/2. Differences in tumor volume between groups were analyzed using two-way ANOVA. B HR-6 or BT-T tumor cells were grown in 3D Matrigel culture for 6 days, and cell lysates were analyzed with western blot. C HR6 cells were implanted into the mammary fat pad of female athymic nude mice. The mice with tumor burden were randomized to treatment with vehicle, trastuzumab, AMD3100, docetaxel, or combinations as indicated. The xenograft tumor lysates were analyzed with western blot.

Published
2023
Full Text
View/download PDF

163. Additional file 7 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Author

Liu, Shuying, Xie, Shelly M., Liu, Wenbin, Gagea, Mihai, Hanker, Ariella B., Nguyen, Nguyen, Singareeka Raghavendra, Akshara, Yang-Kolodji, Gloria, Chu, Fuliang, Neelapu, Sattva S., Marchese, Adriano, Hanash, Samir, Zimmermann, Johann, Arteaga, Carlos L., and Tripathy, Debasish

Abstract

Additional file 7. Figure S7: Effect of combination of AMD3100 and cisplatin or carboplatin on trastuzumab-resistant breast cancer cell growth. BTRT or SKRT cells were grown in 3D Matrigel culture and treated with AMD3100/cisplatin, or AMD3100/carboplatin. Photographs were taken on day 11. Quantitative analysis of the total acini area was performed using AlphaView SA, and the data were analyzed using one-way ANOVA (B, D, F, H: *, P < 0.0001 vs. Vehicle.

Published
2023
Full Text
View/download PDF

164. Additional file 1 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Author

Liu, Shuying, Xie, Shelly M., Liu, Wenbin, Gagea, Mihai, Hanker, Ariella B., Nguyen, Nguyen, Singareeka Raghavendra, Akshara, Yang-Kolodji, Gloria, Chu, Fuliang, Neelapu, Sattva S., Marchese, Adriano, Hanash, Samir, Zimmermann, Johann, Arteaga, Carlos L., and Tripathy, Debasish

Abstract

Additional file 1. Figure S1: Illustration of 3D co-culture. BTRT or SKRT cells were co-cultured with BCAFs in 96-well “U”-bottomed unattached plates. The spheres were treated with AMD3100 on day 3. For three line-co-culture, PBMCs were seeded on day 5, followed by treatment with trastuzumab. Cell viability was detected with CellTiterGlo.

Published
2023
Full Text
View/download PDF

165. Additional file 2 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Author

Liu, Shuying, Xie, Shelly M., Liu, Wenbin, Gagea, Mihai, Hanker, Ariella B., Nguyen, Nguyen, Singareeka Raghavendra, Akshara, Yang-Kolodji, Gloria, Chu, Fuliang, Neelapu, Sattva S., Marchese, Adriano, Hanash, Samir, Zimmermann, Johann, Arteaga, Carlos L., and Tripathy, Debasish

Abstract

Additional file 2. Figure S2. Effect of AMD3100 on cell growth in 3D co-culture. BTRT or SKRT were co-cultured with BCAFs in 96-well “U”-bottomed unattached plates and treated with AMD3100. The dynamic change of the spheres was monitored and photographed.

Published
2023
Full Text
View/download PDF

166. Additional file 3 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Author

Liu, Shuying, Xie, Shelly M., Liu, Wenbin, Gagea, Mihai, Hanker, Ariella B., Nguyen, Nguyen, Singareeka Raghavendra, Akshara, Yang-Kolodji, Gloria, Chu, Fuliang, Neelapu, Sattva S., Marchese, Adriano, Hanash, Samir, Zimmermann, Johann, Arteaga, Carlos L., and Tripathy, Debasish

Abstract

Additional file 3. Figure S3. BTRT cells grown in 3D Matrigel culture were treated with vehicle, AMD3100, trastuzumab, or their combination. SDF-1αwas added at the same time. Cell lysates were subject to RPPA

Published
2023
Full Text
View/download PDF

167. Additional file 5 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Author

Liu, Shuying, Xie, Shelly M., Liu, Wenbin, Gagea, Mihai, Hanker, Ariella B., Nguyen, Nguyen, Singareeka Raghavendra, Akshara, Yang-Kolodji, Gloria, Chu, Fuliang, Neelapu, Sattva S., Marchese, Adriano, Hanash, Samir, Zimmermann, Johann, Arteaga, Carlos L., and Tripathy, Debasish

Abstract

Additional file 5. Figure S5. Western blot. BTRT cells grown in 3D Matrigel culture were treated with vehicle, AMD3100, trastuzumab, or their combination. SDF-1α was added at the same time. A polypeptide that was designed as a CXCR4 antagonist but did not show biological function in the HER2+ breast cancer cells was used as a negative control.

Published
2023
Full Text
View/download PDF

168. Additional file 1 of PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma

Author

Steiner, Raphael E., Parra, Edwin R., Vega, Francisco, Feng, Lei, Westin, Jason R., Neelapu, Sattva S., Strati, Paolo, Green, Michael R., Flowers, Christopher R., Solis, Luisa M., Wistuba, Ignacio I., Ahmed, Sairah, Nair, Ranjit, Hagemeister, Fredrick B., Noorani, Mansoor, and Marques-Piubelli, Mario L.

Abstract

Additional file 1: Methods; Figure S1. Representative pictures showing different cell densities of CD30+PD-L1+ cells. A-C) Multiplex immunofluorescence image of a case with low cell density of CD30+, PD-L1+, and CD30+PD-L1+ cells median: 20.46 cells/mm2, respectively. D-E) Multiplex immunofluorescence image of a case with high cell density of CD30+, PD-L1+, and CD30+PD-L1+ cells (median: 604.62 cells/mm2), respectively. Supplementary Table 1.

Published
2023
Full Text
View/download PDF

171. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Author

Fowler, Nathan H, Davis, R Eric, Rawal, Seema, Nastoupil, Loretta, Hagemeister, Fredrick B, McLaughlin, Peter, Kwak, Larry W, Romaguera, Jorge E, Fanale, Michelle A, Fayad, Luis E, Westin, Jason R, Shah, Jatin, Orlowski, Robert Z, Wang, Michael, Turturro, Francesco, Oki, Yasuhiro, Claret, Linda C, Feng, Lei, Baladandayuthapani, Veerabhadran, Muzzafar, Tariq, Tsai, Kenneth Y, Samaniego, Felipe, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

173. A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy

Author

Ragoonanan, Dristhi, primary, Bhar, Saleh, additional, Mohan, Gopi, additional, Beltramo, Fernando, additional, Khazal, Sajad J., additional, Hurley, Caitlin, additional, Andersen, Clark, additional, Margossian, Steven, additional, Neelapu, Sattva S., additional, Shpall, Elizabeth, additional, Gutierrez, Cristina, additional, Tewari, Priti, additional, Shoberu, Basirat, additional, Talleur, Aimee, additional, McCall, David, additional, Nunez, Cesar, additional, Cuglievan, Branko, additional, Tambaro, Francesco Paolo, additional, Petropoulos, Demetrios, additional, Abdel-Azim, Hisham, additional, and Mahadeo, Kris M., additional

Published
2022
Full Text
View/download PDF

174. Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant

Author

Cherng, Hua‐Jay J., primary, Xu, Guofan, additional, Feng, Lei, additional, Steiner, Raphael, additional, Fayad, Luis, additional, Strati, Paolo, additional, Nair, Ranjit, additional, Nastoupil, Loretta J., additional, Lee, Hun Ju, additional, Neelapu, Sattva S., additional, Flowers, Christopher R., additional, Rodriguez, Maria, additional, Wang, Michael, additional, Hagemeister, Fredrick, additional, Pinnix, Chelsea C., additional, Ramdial, Jeremy, additional, Srour, Samer, additional, Nieto, Yago, additional, Rezvani, Katayoun, additional, Champlin, Richard, additional, Kebriaei, Partow, additional, Westin, Jason, additional, Macapinlac, Homer A., additional, Shpall, Elizabeth, additional, and Ahmed, Sairah, additional

Published
2022
Full Text
View/download PDF

175. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Author

Westin, Jason R, Chu, Fuliang, Zhang, Min, Fayad, Luis E, Kwak, Larry W, Fowler, Nathan, Romaguera, Jorge, Hagemeister, Fredrick, Fanale, Michelle, Samaniego, Felipe, Feng, Lei, Baladandayuthapani, Veerabhadran, Wang, Zhiqiang, Ma, Wencai, Gao, Yanli, Wallace, Michael, Vence, Luis M, Radvanyi, Laszlo, Muzzafar, Tariq, Rotem-Yehudar, Rinat, Davis, R Eric, and Neelapu, Sattva S

Published
2014
Full Text
View/download PDF

176. CT-419 ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Author

Miklos, David, Bharadwaj, Sushma, Holmes, Houston, Oluwole, Olalekan, Jallouk, Andrew, Neelapu, Sattva, Jain, Nitin, Nath, Rajneesh, Munoz, Javier, Bryan, Locke, De Vos, Sven, Eradat, Herbert, Patel, Rushang, Tees, Michael, Tsai, Stephanie, Cahill, Kirk, Sohl, Melhem, Shouse, Geoffrey, Stevens, Don, Fisher, Paul, Feng, Amy, Severyn, Christopher, Le Gall, John, and Locke, Frederick

Published
2024
Full Text
View/download PDF

177. ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Author

Miklos, David, Bharadwaj, Sushma, Holmes, Houston, Oluwole, Olalekan, Jallouk, Andrew, Neelapu, Sattva, Jain, Nitin, Nath, Rajneesh, Munoz, Javier, Bryan, Locke, De Vos, Sven, Eradat, Herbert, Patel, Rushang, Tees, Michael, Tsai, Stephanie, Cahill, Kirk, Sohl, Melhem, Shouse, Geoffrey, Stevens, Don, Fisher, Paul, Feng, Amy, Severyn, Christopher, Le Gall, John, Locke, Frederick, and Pinilla, Javier

Published
2024
Full Text
View/download PDF

181. Cutaneous/ Subcutaneous Involvement - an Immuneprivileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.

Author

Nair, Ranjit, Prakash, Rishab, Dang, Anna, Gunther, Jillian R., Huen, Auris, Xu, Jie, Malpica Castillo, Luis Enrique, Torres Cabala, Carlos, Heberton, Meghan, Fang, Penny, Ahmed, Sairah, Miranda, Roberto N., Fayad, Luis, Steiner, Raphael, Lee, Hun Ju, Chihara, Dai, Jain, Preetesh, Srour, Samer A, Ramdial, Jeremy L, Nieto, Yago, Nastoupil, Loretta J., Pinnix, Chelsea C., Neelapu, Sattva S., Flowers, Christopher R., Medeiros, L. Jeffrey, Hosing, Chitra, Wang, Michael L., Dabaja, Bouthaina S., Vega, Francisco, Feng, Lei, and Iyer, Swaminathan Padmanabhan

Published
2022
Full Text
View/download PDF

182. T-cell potential for CD19-expressing malignancies revealed by multi-dimensional single-cell profiling

Author

Rezvan, Ali, primary, Romain, Garbrielle, additional, Fathi, Mohsen, additional, Heeke, Darren, additional, Martinez-Paniagua, Melisa, additional, An, Xingyue, additional, Bandey, Irfan N, additional, Saeedi, Arash, additional, Sadeghi, Fatemeh, additional, Fousek, Kristen, additional, Puebla-Osorio, Nahum, additional, Cooper, Laurence JN, additional, Bernatchez, Chantale, additional, Singh, Harjeet, additional, Ahmed, Nabil, additional, Mattie, Mike, additional, Bot, Adrian, additional, Neelapu, Sattva, additional, and Varadarajan, Navin, additional

Published
2022
Full Text
View/download PDF

183. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, additional, Marques-Piubelli, Mario L., additional, Dai, Enyu, additional, Dang, Minghao, additional, Ma, Man Chun John, additional, Li, Xubin, additional, Yang, Haopeng, additional, Henderson, Jared, additional, Kudryashova, Olga, additional, Meerson, Mark, additional, Isaev, Sergey, additional, Kotlov, Nikita, additional, Nomie, Krystle J., additional, Bagaev, Alexander, additional, Parra, Edwin R., additional, Solis Soto, Luisa M., additional, Parmar, Simrit, additional, Hagemeister, Fredrick B., additional, Ahmed, Sairah, additional, Iyer, Swaminathan P., additional, Samaniego, Felipe, additional, Steiner, Raphael, additional, Fayad, Luis, additional, Lee, Hun, additional, Fowler, Nathan H., additional, Flowers, Christopher R., additional, Strati, Paolo, additional, Westin, Jason R., additional, Neelapu, Sattva S., additional, Nastoupil, Loretta J., additional, Vega, Francisco, additional, Wang, Linghua, additional, and Green, Michael R., additional

Published
2022
Full Text
View/download PDF

184. Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma.

Author

Steiner, Raphael Eric, primary, Strati, Paolo, additional, Flowers, Christopher, additional, Neelapu, Sattva Swarup, additional, Green, Michael Richard, additional, Nastoupil, Loretta J., additional, Hagemeister, Fredrick B., additional, Feng, Lei, additional, Ahmed, Sairah, additional, Nair, Ranjit, additional, Fayad, Luis, additional, Lee, Hun Ju, additional, Rodriguez, Maria Alma, additional, and Westin, Jason, additional

Published
2022
Full Text
View/download PDF

185. Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma.

Author

Cherng, Hua-Jay Jeffery, primary, Alig, Stefan, additional, Oki, Yasuhiro, additional, Nastoupil, Loretta J., additional, Fayad, Luis, additional, Neelapu, Sattva Swarup, additional, Turturro, Francesco, additional, Hagemeister, Frederick B., additional, Rodriguez, Maria Alma, additional, Lee, Hun Ju, additional, McDonnell, Timothy, additional, Flowers, Christopher, additional, Vega, Francisco, additional, Green, Michael Richard, additional, Alizadeh, Ash A., additional, Davis, Richard Eric, additional, and Westin, Jason, additional

Published
2022
Full Text
View/download PDF

186. A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies.

Author

Neelapu, Sattva Swarup, primary, Hamadani, Mehdi, additional, Miklos, David Bernard, additional, Holmes, Houston, additional, Hinkle, John, additional, Kennedy-Wilde, Jackie, additional, Maller, Ori, additional, Weinstein, Maggie, additional, Galimi, Francesco, additional, Lai, Rose, additional, and Stevens, Don A., additional

Published
2022
Full Text
View/download PDF

187. Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function.

Author

Mamlouk, Omar, primary, Strati, Paolo, additional, Feng, Lei, additional, Sun, Ryan, additional, Steiner, Raphael Eric, additional, Nair, Ranjit, additional, Flowers, Christopher, additional, Ramdial, Jeremy L, additional, Saini, Neeraj, additional, Srour, Samer Ali, additional, Champlin, Richard E., additional, Kebriaei, Partow, additional, Nastoupil, Loretta J., additional, Rodriguez, Maria Alma, additional, Shpall, Elizabeth J., additional, Nieto, Yago, additional, Westin, Jason, additional, Neelapu, Sattva Swarup, additional, Mandayam, Sreedhar, additional, and Ahmed, Sairah, additional

Published
2022
Full Text
View/download PDF

188. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade

Author

Singh, Shubhra, primary, Roszik, Jason, additional, Saini, Neeraj, additional, Singh, Vipul Kumar, additional, Bavisi, Karishma, additional, Wang, Zhiqiang, additional, Vien, Long T., additional, Yang, Zixi, additional, Kundu, Suprateek, additional, Davis, Richard E., additional, Bover, Laura, additional, Diab, Adi, additional, Neelapu, Sattva S., additional, Overwijk, Willem W., additional, Rai, Kunal, additional, and Singh, Manisha, additional

Published
2022
Full Text
View/download PDF

189. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma

Author

Saini, Neeraj Y., primary, Swoboda, David M., additional, Greenbaum, Uri, additional, Ma, Junsheng, additional, Patel, Romil D., additional, Devashish, Kartik, additional, Das, Kaberi, additional, Tanner, Mark R., additional, Strati, Paolo, additional, Nair, Ranjit, additional, Fayad, Luis, additional, Ahmed, Sairah, additional, Lee, Hun Ju, additional, Iyer, Swaminathan P., additional, Steiner, Raphael, additional, Jain, Nitin, additional, Nastoupil, Loretta, additional, Loghavi, Sanam, additional, Tang, Guilin, additional, Bassett, Roland L., additional, Jain, Preetesh, additional, Wang, Michael, additional, Westin, Jason R., additional, Green, Michael R., additional, Sallman, David A., additional, Padron, Eric, additional, Davila, Marco L., additional, Locke, Frederick L., additional, Champlin, Richard E., additional, Garcia-Manero, Guillermo, additional, Shpall, Elizabeth J., additional, Kebriaei, Partow, additional, Flowers, Christopher R., additional, Jain, Michael D., additional, Wang, Feng, additional, Futreal, Andrew P., additional, Gillis, Nancy, additional, Neelapu, Sattva S., additional, and Takahashi, Koichi, additional

Published
2022
Full Text
View/download PDF

190. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy

Author

Al Zaki, Ajlan, primary, Feng, Lei, additional, Watson, Grace, additional, Ahmed, Sairah A., additional, Mistry, Haleigh, additional, Nastoupil, Loretta J., additional, Hawkins, Misha, additional, Nair, Ranjit, additional, Iyer, Swaminathan P., additional, Lee, Hun J., additional, Steiner, Raphael E., additional, Flowers, Christopher R., additional, Shpall, Elizabeth J., additional, Kebriaei, Partow, additional, Neelapu, Sattva S., additional, Westin, Jason R., additional, and Strati, Paolo, additional

Published
2022
Full Text
View/download PDF

192. Multiomic dynamic single-cell profiling of CAR T cell populations associated with efficacy

Author

Rezvan, Ali, primary, Romain, Gabrielle, additional, Fathi, Mohsen, additional, Heeke, Darren, additional, Martinez-Paniagua, Melisa, additional, An, Xingyue, additional, Bandey, Irfan N, additional, Liadi, Ivan, additional, Cooper, Laurence J.N., additional, Singh, Harjeet, additional, Bot, Adrian, additional, Neelapu, Sattva, additional, and Varadarajan, Navin, additional

Published
2022
Full Text
View/download PDF

195. The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

Author

Chihara, Dai, Fanale, Michelle A., Miranda, Roberto N., Noorani, Mansoor, Westin, Jason R., Nastoupil, Loretta J., Hagemeister, Fredrick B., Fayad, Luis E., Romaguera, Jorge E., Samaniego, Felipe, Turturro, Francesco, Lee, Hun J., Neelapu, Sattva S., Rodriguez, M. Alma, Wang, Michael, Fowler, Nathan H., Davis, Richard E., Medeiros, L. Jeffrey, Hosing, Chitra, Nieto, Yago L., and Oki, Yasuhiro

Published
2017
Full Text
View/download PDF

196. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma.

Author

Steiner, Raphael E., Parra, Edwin R., Vega, Francisco, Feng, Lei, Westin, Jason R., Neelapu, Sattva S., Strati, Paolo, Green, Michael R., Flowers, Christopher R., Solis, Luisa M., Wistuba, Ignacio I., Ahmed, Sairah, Nair, Ranjit, Hagemeister, Fredrick B., Noorani, Mansoor, and Marques-Piubelli, Mario L.

Subjects
MACROPHAGES, PROGNOSIS, THYMUS tumors, NON-Hodgkin's lymphoma, LYMPHOMAS, DISEASE relapse
Abstract

Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standard-of-care immunochemotherapy, patients who have disease relapse have an unfavorable prognosis. Pre-treatment prognostic biomarkers in PMBCL are needed. In this retrospective study, we analyzed the clinical features and outcomes of PMBCL patients and their association with immune cell subpopulations identified by multiplex immunofluorescence at initial diagnosis. Two different antibody panels were used to assess macrophages in tissue biopsy specimens collected before the initiation of induction therapy. Twelve PMBCL patients, including five patients who had disease relapse, were included in the analysis. At a median follow-up time of 32.2 months, the median progression-free and overall survival durations were not reached. Our findings suggest that a high density of PD-L1+ macrophages is associated with favorable features, such as early disease stage and the absence of B-symptoms, and indicate that a high percentage of PD-L1+ macrophages and high densities of CD30+PD-L1+ cells and CD30+ cells might be associated with a lower risk of relapse within 12 months of therapy initiation. Further studies are needed to develop a biomarker signature predictive of treatment response with therapeutic consequences for patients with newly diagnosed PMBCL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

200. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

Author

Wang, Michael, Fayad, Luis, Wagner-Bartak, Nicolaus, Zhang, Liang, Hagemeister, Fredrick, Neelapu, Sattva S, Samaniego, Felipe, McLaughlin, Peter, Fanale, Michelle, Younes, Anas, Cabanillas, Fernando, Fowler, Nathan, Newberry, Kate J, Sun, Luhong, Young, Ken H, Champlin, Richard, Kwak, Larry, Feng, Lei, Badillo, Maria, Bejarano, Maria, Hartig, Kimberly, Chen, Wendy, Chen, Yiming, Byrne, Catriona, Bell, Neda, Zeldis, Jerome, and Romaguera, Jorge

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results